多家创新药企迎来“自我造血”节点！可T+0交易的港股创新药ETF(159567)现涨0.82%，实时成交额突破6亿元排名同指数第一

Group 1 - Several innovative pharmaceutical companies have reached a profitability turning point or continued to narrow losses in Q1, driven primarily by self-sustaining growth from the continuous expansion of main products [1] - In Q1, Innovent Biologics achieved revenue of 380 million yuan, a year-on-year increase of 129.9%, with a net profit of 14 million yuan. BeiGene reported revenue of 8.048 billion yuan, a year-on-year increase of 50.2%, with losses narrowing from 1.908 billion yuan to 94.503 million yuan [1] - The Hong Kong innovative drug sector has seen high profitability continue to digest valuations, with the Hong Kong innovative drug index's price-to-earnings ratio dropping from 64 times on February 21 to 25 times on May 19, highlighting significant value for current investments [1] Group 2 - The Hong Kong innovative drug ETF (159567) tracks the Guozheng Hong Kong Stock Connect Innovative Drug Index, with 90% of its weight in innovative drug companies, positioning it to benefit from trends such as AI-enabled drug development and the expansion of domestic innovative drugs overseas [2] - The innovative drug ETF (159992) tracks an index that includes leading companies in the innovative drug industry chain, benefiting from advancements in AI, the export of domestic innovative drugs, and the introduction of new insurance policies for high-priced innovative drugs [2] - Huaxin Securities believes the innovative drug sector currently exhibits significant investment value, with Chinese companies establishing technological advantages in cutting-edge fields and attracting attention from large multinational pharmaceutical companies [2]